Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis,
Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX)
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS,
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. ("Abivax" or "the
NEW YORK, June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ABIVAX Societe Anonyme (NASDAQ:ABVX).
Shareholders
